



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/564,706	01/13/2006	Ian M. Bell	21172YP	1708
210	7590	01/27/2009	EXAMINER	
MERCK AND CO., INC P O BOX 2000 RAHWAY, NJ 07065-0907			DAVIS, ZINNA NORTHINGTON	
ART UNIT	PAPER NUMBER			
	1625			
MAIL DATE	DELIVERY MODE			
01/27/2009	PAPER			

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/564,706	Applicant(s) BELL ET AL.
	Examiner Zinna Northington Davis	Art Unit 1625

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED. (35 U.S.C. § 133).

Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 07 November 2008.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-16,18 and 25 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 1-3,9,11,12,15 and 16 is/are rejected.

7) Claim(s) 4-8, 10, 13, 14, 18 and 25 is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO/SB/08)
 Paper No(s)/Mail Date 01/13/08.


4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date _____.

5) Notice of Informal Patent Application

6) Other: _____

DETAILED ACTION

1. Claims 1-16, 18, and 25 are pending. Claims 17 and 19-24 have been canceled.
2. In the response filed November 7, 2008, Applicants have elected Group I, claims 1-16, without traverse. Applicants also identify the compound at page 27 as the preferred species. The compound is depicted below:



3. Based upon the response filed November 7, 2008, the restriction requirement and election of species requirement are withdrawn. The claims are examined as a whole.
4. Claims 1, 15, and 16 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
 - A. At claim 1, page 3, line 24, the recitation of the phrase "as well as" is improper.
 - B. At claim 1, page 4, line 2, the phrase "with one or more of" should be amended to read as --with one or more of--.
 - C. It is suggested that the phrase "and pharmaceutically acceptable salts and individual diastereomers" should be amended to read as in the alternative.

D. Claim 16 should recite an effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:


A person shall be entitled to a patent unless --

(b) The invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.


6. Claims 1-3, 9, 11, 12, and 16 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Merck& Co., Inc. (Reference A3, cited by Applicants).

The instantly claimed compounds are disclosed. At page 284, see example 152.


At page 285, see example 153. At page 286, see example 154. At page 287, see example 155. At page 288, see example 156. At page 324, see example 182. The compounds are depicted below:




Example 152,




Example 153,




Example 154,



Example 155,



Example 156, and



Example 182.

7. The Information Disclosure Statement filed January 13, 2006 has been considered.
8. Claims 4-8, 10, 13, 14, 18 and 25 are objected to.
9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zinna Northington Davis whose telephone number is 571-272-0682.

10. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

11. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Zinna Northington Davis/
Zinna Northington Davis
Primary Examiner
Art Unit 1625

Znd
01.23.2009